← Leaderboards
Kevin Trabbic
Bluewillow Biologics, Inc.
$2,751,795
Attributed
$2,751,795
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $987.5K · FY2022–24$1M$750K$500K$250K$0
'22
'23
'24
Funding mix
By agency
NIH$2,751,795 · 2
By mechanism
R44$2,751,795 · 2
Top collaborators
No co-investigators on record.
Most similar at Bluewillow Biologics, Inc.
Same institution · by research overlap
- Shyamala Ganesan$853,503
Others in their field
Other Rising Stars on “Mucosal Immunity”
- Christina Millin · Rho Federal Systems Division, Inc.$32,128,916
- Li Liang · University Of California-Irvine$7,511,446
- Elizabeth Norton · Tulane University Of Louisiana$4,695,387
- Ronald Veazey · Tulane University Of Louisiana$3,519,091
- Christian Furlan Freguia · Rise Therapeutics, Llc$3,092,139
- Nathan Schuldt · University Of Minnesota$2,999,774
Research focus
Mucosal ImmunityProteinsImmunizationMedicalPathogenProductionFormulationImmune ResponseImmunogenicityManufacturing ProcessNanoemulsionBiological ProductsPreservationPreventAntigensCyclic GmpAdjuvantGlobal HealthClinical MaterialClinical TrialsInfectionChildMucous MembraneRecurrent Infection
Grant awards (3)
Development of a Mucosal Nanoemulsion-Adjuvanted RSV Vaccine using Recombinant Pre-Fusion F Protein$891,695
R44 · FY2024 · AI · contact PI
Development of a Mucosal Nanoemulsion-Adjuvanted RSV Vaccine using Recombinant Pre-Fusion F Protein$872,585
R44 · FY2023 · AI · contact PI
Pre-Clinical Development of a Intranasal Bivalent gD2/gB2 HSV-2 Mucosal Vaccine$987,515
R44 · FY2022 · AI · contact PI